A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
About this study
The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
- Condition
- Alzheimer's Disease
- Tested
- No Intervention
- Sponsor
- Eisai Korea Inc.
Who can join
- Age
- 19 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 19 years
- Study condition: Alzheimer's Disease
- Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
- The clinical decision to treat with LEQEMBI has already been made
- Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.
Exclusion 1
- Currently participating in an interventional clinical study
Where
1 site, 1 recruiting
Eisai Trial Site #1
Nutley, New Jersey, United States
Contact
-
Eisai Korea Inc. Medical department Serena SoYoun Kwon
+82-2-3451-5533 s-kwon@eisaikorea.com
Potential match only. Final eligibility is determined by the study team.